TTI

Tetra Technologies Inc
NYSEINDUSTRIALSCONGLOMERATES

Key Statistics

Market Cap
$1.38B
P/E Ratio
155.50
EPS
$0.06
Beta
1.19
52W High
$12.54
52W Low
$3.17
50-Day MA
$10.13
200-Day MA
$9.03
Dividend Yield
Profit Margin
1.16%
Forward P/E
12.71
PEG Ratio
1.82

About Tetra Technologies Inc

TETRA Technologies, Inc. is a diversified oil and gas services company. The company is headquartered in The Woodlands, Texas.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$630.04M
Gross Profit (TTM)$192.04M
EBITDA$90.24M
Operating Margin8.20%
Return on Equity3.04%
Return on Assets5.20%
Revenue/Share (TTM)$4.71
Book Value$2.12
Price-to-Book4.84
Price-to-Sales (TTM)2.19
EV/Revenue2.505
EV/EBITDA18.36
Quarterly Earnings Growth (YoY)100.00%
Quarterly Revenue Growth (YoY)-0.60%
Shares Outstanding$147.82M
Float$127.64M
% Insiders5.45%
% Institutions80.89%

Historical Volatility

HV 10-Day
85.46%
HV 20-Day
64.64%
HV 30-Day
71.18%
HV 60-Day
55.91%
HV Rank
74.6%

Volatility is currently expanding

Analyst Ratings

Consensus ($13.12 target)
1
Strong Buy
3
Buy

Latest News

TETRA TECHNOLOGIES INTRODUCES TETRA NEPTUNE Z-LITE DEEPWATER COMPLETIONS FLUID

Using Neptune Chemistry to Achieve Required Density With Lower Zinc Content; Awarded Three-Well 20k psi Deepwater Project in the Gulf of America With Estimated Start in 2026 SPRING, Texas, June 29, 2026 /PRNewswire/ -- TETRA Technologies, Inc. (NYSE: TTI) today announced the introduction of TETRA Neptune Z-Lite, a high-density completion fluid designed for deepwater and high-pressure well applications. The fluid system uses our patented Neptune fluid chemistry and expands the Company's completion fluids portfolio by offering up to 60% lower zinc-ion concentration than conventional zinc-based fluids while maintaining required density performance.

PRNewsWire6/29/2026Neutral
Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors

San Diego, California--(Newsfile Corp. - June 17, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation cysteamine-based therapies for rare diseases, including cystinosis and primary mitochondrial diseases, today announced the appointment of Gilad Aharon, PhD, to its Board of Directors. Dr. Aharon is a Co-Founder and Portfolio Manager at Rosalind Advisors, Inc., a Toronto-based life sciences institutional investor.

Newsfile Corp6/17/2026Neutral
TETRA Technologies, Inc. Announces Pricing of Public Offering of Common Stock

SPRING, Texas, June 2, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) today announced the pricing of an underwritten public offering of 10,810,811 shares of its common stock, par value $0.01 per share ("Common Stock"), at a price to the public of $9.25 per share, pursuant to an effective shelf registration statement on Form S-3 (the "Registration Statement") filed with the U.S. Securities and Exchange Commission (the "SEC"). The Company intends to use the net proceeds it receives from the offering for general corporate purposes, including funding a portion of the construction costs of its Arkansas bromine project.

PRNewsWire6/3/2026Neutral
TETRA TECHNOLOGIES, INC. ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

SPRING, Texas, June 2, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) today announced the commencement of an underwritten public offering of $100 million of shares of its common stock, par value $0.01 per share ("Common Stock"), pursuant to an effective shelf registration statement on Form S-3 (the "Registration Statement") filed with the U.S. Securities and Exchange Commission (the "SEC"). The Company intends to use the net proceeds it receives from the offering for general corporate purposes, including funding a portion of the construction costs of its Arkansas bromine project.

PRNewsWire6/2/2026Neutral
TETRA Technologies: Deep In The Oil Patch, A Critical Minerals Play Is Taking Shape

TETRA Technologies reported decade-high Q1 2026 revenue and EBITDA, with EPS coming 100% above estimates despite flat year-over-year growth. The company is constructing an Arkansas bromine facility for zinc bromide electrolyte battery supply. This is the project that contributes to the growth of the company in the near future. At 14x EV/EBITDA, TTI trades at the same multiple as Generac, although TTI holds bromine supply chain exposure and dominant deepwater completion fluid market share.

Seeking Alpha5/11/2026Positive
TETRA TECHNOLOGIES, INC. REPORTS STRONG FIRST-QUARTER 2026 RESULTS MAINTAINS 2026 GUIDANCE

SPRING, Texas, April 29, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) announced financial results for the three months ended March 31, 2026. First-Quarter 2026 Financial Highlights Revenues of $156.3 million Income from continuing operations of $8.3 million, inclusive of $0.5 million of unusual charges Adjusted EBITDA of $25.6 million Income per share from continuing operations of $0.06 Brady Murphy, TETRA's President and Chief Executive Officer, stated, "We are pleased to start 2026 with one of the strongest first quarter performances in the company's past ten years.

PRNewsWire4/29/2026Neutral

More INDUSTRIALS Stocks

Data last updated: 7/9/2026